The Mid-Atlantic Region State and Local Economic Development Award recognizes successful initiatives that involve partnership between state or local economic development groups and federal laboratories for economic benefit in the region.
Multiple sclerosis (MS) is a disease of the central nervous system in which the immune system attacks the brain and spinal cord, typically resulting in muscle weakness, problems with vision and coordination, pain, and, in some patients, cognitive impairments. The disorder affects approximately 400,000 people in the U.S. and more than 2.5 million people worldwide. Patients with relapsing forms of MS are currently treated with one of three FDA-approved interferon-beta agents or with glatiramer acetate.
Multiple sclerosis (MS) is a disease of the central nervous system in which the immune system attacks the brain and spinal cord, typically resulting in muscle weakness, problems with vision and coordination, pain, and in some patients, cognitive impairments. The disorder affects approximately 400,000 people in the U.S. and more than 2.5 million people worldwide. Patients with relapsing forms of MS are currently treated with one of three FDA-approved interferon beta agents or with glatiramer acetate.
Natural products have formed the basis of traditional medicine systems for thousands of years and have been the single most productive source of leads for the development of cancer drugs. This nomination describes the discovery of halichondrin B, a compound isolated from a species of marine sponge, and the subsequent preclinical and clinical research and development of a related synthetic compound into the novel cancer drug Eribulin.
The emergence of bioinformatics tools, which integrate molecular biology and genomics with computer based information technology, is bringing about a revolution in our understanding of the molecular mechanisms underlying normal and dysfunctional biological processes. The microarray is one such tool that caused a paradigm shift in the manner in which researchers collect and analyze genetic data.
Representative of the Year
Tom Stackhouse, Ph.D., is Associate Director of the Technology Transfer Center at the National Cancer Institute (NCI). The Center serves as the focal point for the implementation of legislation relating to collaborative agreements and inventions for the NCI, including the Frederick National Laboratory of Cancer Research. Dr. Stackhouse oversees the satellite office located in the Frederick National Laboratory of Cancer Research, which provides a full range of technology transfer services to NCI’s scientists located in Frederick.
Currently, there are no FDA-approved therapies for Niemann-Pick disease type-C1 (NPC). NPC is a rare lethal genetic lysosomal storage disorder that results in an accumulation of cholesterol in the liver and spleen and eventually leads to neurodegeneration. 2-hydroxypropyl-β-cyclodextrin (HPβCD) is a cyclodextrin typically used by the pharmaceutical industry as an excipient. Studies of NPC in animal models have shown that HPβCD can reduce the biochemical burden associated with NPC, improving neurological pathology, decreasing neurological dysfunction, and increasing lifespan.
In April 2013, President Obama unveiled the “BRAIN” initiative, which called on the scientific community to better understand the human brain in an effort to treat, prevent, and cure neurological diseases. For example, anxiety, depression, substance abuse, and post-traumatic stress are a few pervasive neuropsychiatric diseases that afflict more than 150 million people in developed countries, and approximately 15 million of those are in the U.S.
The National Cancer Institute (NCI), in partnership with the nonprofit Center for Advancing Innovation (CAI) and the Avon Foundation for Women, launched The Breast Cancer Startup Challenge, a first-of-a-kind, international, university-based competition. Through the creation of startup companies, it represents a new
model to accelerate the transfer of federally funded inventions to the marketplace, specifically focused on increasing the volume of developing emerging breast cancer technologies.
Medical research to combat disease is now a global effort and one that now requires an international technology transfer effort to see that new discoveries from research are effectively developed and commercialized to reach patients. While the United States in general, and the National Institutes of Health (NIH) in particular, have long led the way in effective biomedical technology transfer, such is not the case with new or younger transfer programs at research institutions outside the US, especially those in emerging and middle-income countries.